未登录

M

Michael R. Zalutsky

department of radiology

H指数:70

被引数:1.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

191Pt-labeled trithiol-Hoechst-PSMA: preliminary evaluation of conjugates designed for delivery to genomic DNA of PSMA-positive cancers

191Pt标记的三巯基-霍希斯特-PSMA：靶向PSMA阳性癌症基因组DNA的缀合物的初步评估

EJNMMI Radiopharmacy and Chemistry

IF3.3

2026-01-090

OAAI

Effective treatment of human prostate carcinoma xenografts with Single-Dose PSMA-targeted [211At]YF2

单次剂量PSMA靶向[211At]YF2对人类前列腺癌异种移植瘤的有效治疗

European Journal of Nuclear Medicine and Molecular Imaging

IF7.6

2025-10-300

PRE

Trithiol ligand provides tumor-targeting 191Pt-complexes with high molar activity and promising in vivo properties

三硫配体为肿瘤靶向的191Pt-复合物提供了高摩尔活性和有前景的体内特性。

Nuclear Medicine and Biology

IF3

2025-06-100

PRE

Enhancing the therapeutic index of [211At]YF2 with iodo pseudo carrier: A simple strategy for reducing accumulation in kidneys, salivary and lacrimal glands

通过碘假载体增强[211At]YF2的治疗指数：一种减少在肾脏、唾液腺和泪腺中积累的简单策略

Nuclear Medicine and Biology

IF3

2025-05-110

PRE

PSMA-reactive NB7 single domain antibody fragment: A potential scaffold for developing prostate cancer theranostics

NUCLEAR MEDICINE AND BIOLOGY

IF3

2024-07-012

PRE

A third generation PSMA-targeted agent [211At]YF2: Synthesis and in vivo evaluation

NUCLEAR MEDICINE AND BIOLOGY

IF3

2024-07-013

PRE

DNA Repair Inhibitors: Potential Targets and Partners for Targeted Radionuclide Therapy

IF5.5

2023-07-118

OAAI

Site-Specific Radiohalogenation of a HER2-Targeted Single-Domain Antibody Fragment Using a Novel Residualizing Prosthetic Agent

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2022-11-1111

OA

Brachytherapy via a depot of biopolymer-bound 131I synergizes with nanoparticle paclitaxel in therapy-resistant pancreatic tumours

NATURE BIOMEDICAL ENGINEERING

IF26.6

2022-10-1918

OA

Low-level whole-brain radiation enhances theranostic potential of single-domain antibody fragments for human epidermal growth factor receptor type 2 (HER2)-positive brain metastases

NEURO-ONCOLOGY ADVANCES

IF4.1

2022-08-231

OAAI

Effective Treatment of Human Breast Carcinoma Xenografts with Single-Dose 211At-Labeled Anti-HER2 Single-Domain Antibody Fragment

JOURNAL OF NUCLEAR MEDICINE

IF9.1

2022-05-2613

OA

Evaluation of an 131I-labeled HER2-specific single domain antibody fragment for the radiopharmaceutical therapy of HER2-expressing cancers

SCIENTIFIC REPORTS

IF3.9

2022-02-2221

OAAI

Gold Nanostars: A Novel Platform for Developing 211At-Labeled Agents for Targeted Alpha-Particle Therapy

INTERNATIONAL JOURNAL OF NANOMEDICINE

IF6.5

2021-10-0115

OAAI

Production, purification and availability of 211At: Near term steps towards global access

NUCLEAR MEDICINE AND BIOLOGY

IF3

2021-09-0150

OAAI

Labeling single domain antibody fragments with 18F using a novel residualizing prosthetic agent - N-succinimidyl 3-(1-(2-(2-(2-(2-[18F] fluoroethoxy)ethoxy)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)-5-(guanidinomethyl)benzoate

NUCLEAR MEDICINE AND BIOLOGY

IF3

2021-09-016

OAAI

An Improved 211At-Labeled Agent for PSMA-Targeted α-Therapy

JOURNAL OF NUCLEAR MEDICINE

IF9.1

2021-06-0446

OA

Feasibility of Developing Radiotracers for MDM2: Synthesis and Preliminary Evaluation of an 18F-Labeled Analogue of the MDM2 Inhibitor SP-141

PHARMACEUTICALS

IF4.8

2021-04-133

OAAI

Synthesis and preliminary evaluation of 211At-labeled inhibitors of prostate-specific membrane antigen for targeted alpha particle therapy of prostate cancer

NUCLEAR MEDICINE AND BIOLOGY

IF3

2021-03-0121

OAAI

Site-Specific and Residualizing Linker for 18F Labeling with Enhanced Renal Clearance: Application to an Anti-HER2 Single-Domain Antibody Fragment

JOURNAL OF NUCLEAR MEDICINE

IF9.1

2021-02-2613

OA

Site-specific radioiodination of an anti-HER2 single domain antibody fragment with a residualizing prosthetic agent

NUCLEAR MEDICINE AND BIOLOGY

IF3

2021-01-0120

OAAI